m+Medelevator.RU
← Поиск публикаций
Veterinarni medicina · 2025

Antioxidant and cytokine modulation in PCOS rats protected with probiotics, myo-inositol, and herbal extracts.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zaki Abdelkader Ahmed, Alharbi Naif Muqbil, Almundarij Tariq Ibrahim, Albarrak Saleh Mohammed

Аннотация

This study investigated the pathophysiology of polycystic ovarian syndrome (PCOS) and evaluated the protective effects of various treatments in immature female Wistar rats (N = 48). The rats were divided into 6 groups: Olive oil injection (negative control, G1); testosterone propionate (TP)-induced PCOS (G2); probiotic + TP (G3); myo-inositol (myo-ins) + TP (G4); U. dioica extract + TP (G5); W. somnifera extract + TP (G6). The body weight, body weight gain, and percentage gain were measured weekly and then transformed using the base-10 logarithm (log10). TNF-α, IL-4, IL-10, and IL-17 were weekly measured using ELISA kits. Glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT) were analysed in the serum and liver extracts. The W. somnifera significantly reduced the TNF-α levels (P < 0.01). The probiotic and myo-ins significantly elevated the IL-10 levels (P < 0.01). Both plant extracts moderately restored the IL-10 levels. The probiotic and U. dioica administration significantly reduced the IL-17 levels (P < 0.01). The W. somnifera administration also decreased the IL-17 levels, though the effect was less pronounced than that of U. dioica. The probiotic, myo-ins, and W. somnifera groups exhibited enhanced CAT activity (P < 0.05). W. somnifera showed significant increases in the SOD and GSH-Px activities (P < 0.01), showing the most dramatic improvement. The use of these four treatments as a monotherapy in this study resulted in different changes. Therefore, further investigation is necessary to evaluate the protective effects of combining duos or trios of these treatments against this disease.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты